Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma

被引:18
|
作者
Luo, Yi [1 ,2 ]
Song, Lei [1 ,2 ]
Wang, Xinyu [3 ]
Huang, Yujie [1 ,2 ]
Liu, Yongqiang [1 ,2 ]
Wang, Qi [1 ,2 ]
Hong, Ming [1 ,2 ]
Yuan, Zhongyu [3 ]
机构
[1] Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou, Peoples R China
[2] Guangzhou Univ Chinese Med, Inst Clin Pharmacol, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China
关键词
hepatocellular carcinoma; cryptotanshinone; system pharmacology; apoptosis; autophagy; PI3K/AKT/MTOR PATHWAY; SYSTEMS PHARMACOLOGY; NATURAL-PRODUCTS; CELL-DEATH; IN-VIVO; CANCER; APOPTOSIS; AUTOPHAGY; INHIBITION; TARGET;
D O I
10.3389/fphar.2020.01264
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatocellular carcinoma (HCC) is a fatal and dominant form of liver cancer that currently has no effective treatment or positive prognosis. In this study, we explored the antitumor effects of cryptotanshinone (CPT) against HCC and the molecular mechanisms underlying these effects using a systems pharmacology and experimental validation approach. First, we identified a total of 296 CPT targets, 239 of which were also HCC-related targets. We elucidated the mechanisms by which CPT affects HCC through multiple network analysis, including CPT-target network analysis, protein-protein interaction network analysis, target-function network analysis, and pathway enrichment analysis. In addition, we found that CPT induced apoptosis in Huh7 and MHCC97-H ells due to increased levels of cleaved PARP, Bax, and cleaved caspase-3 and decreased Bcl-2 expression. CPT also induced autophagy in HCC cells by increasing LC3-II conversion and the expression of Beclin1 and ATG5, while decreasing the expression of p62/SQSTM1. Autophagy inhibitors (3-methyladenine and chloroquine) enhanced CPT-induced proliferation and apoptosis, suggesting that CPT-induced autophagy may protect HCC cells against cell death. Furthermore, CPT was found to inhibit the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway. Interestingly, activation of PI3K by insulin-like growth factor-I inhibited CPT-induced apoptosis and autophagy, suggesting that the PI3K/AKT/mTOR signaling pathway is involved in both CPT-induced apoptosis and autophagy. Finally, CPT was found to inhibit the growth of Huh7 xenograft tumors. In conclusion, we first demonstrated the antitumor effects of CPT in Huh7 and MHCC97-H cells, bothin vitroandin vivo. We elucidated the potential antitumor mechanism of CPT, which involved inducing apoptosis and autophagy by inhibiting the PI3K/Akt/mTOR signaling pathway. Our findings may provide valuable insights into the clinical application of CPT, serving as a potential candidate therapeutic agent for HCC treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets
    Klingenberg, Marcel
    Matsuda, Akiko
    Diederichs, Sven
    Patel, Tushar
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (03) : 603 - 618
  • [32] Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review
    Qiang, Zeyuan
    Wan, Juan
    Chen, Xiangzheng
    Wang, Haichuan
    [J]. TRANSLATIONAL CANCER RESEARCH, 2024, 13 (06) : 3156 - 3178
  • [33] Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives
    Roth, Gael S.
    Decaens, Thomas
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 87 : 101 - 112
  • [34] Mechanisms and Therapeutic Strategies of Chronic Infection and Inflammation-Associated Hepatocellular Carcinoma
    Peng Zheng
    Li Chang-Fei
    Hao Jun-Li
    Meng Song-Dong
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2014, 41 (01) : 17 - 23
  • [35] Hot Topic: Recent Advances Into the Molecular Mechanisms and Therapeutic Targeting of Hepatocellular Carcinoma
    Chua, Mei-Sze
    Wang, Li
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2011, 11 (06) : 491 - 492
  • [36] Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma
    Altomonte, Jennifer
    Marozin, Sabrina
    Schmid, Roland M.
    Ebert, Oliver
    [J]. MOLECULAR THERAPY, 2010, 18 (02) : 275 - 284
  • [37] Therapeutic advances in hepatocellular carcinoma
    Poupon, Raoul
    Fartoux, Laetitia
    Rosmorduc, Olivier
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2008, 192 (01): : 23 - 31
  • [38] Therapeutic approaches to hepatocellular carcinoma
    Borgia, Beatrice
    Neri, Dario
    [J]. DRUGS OF THE FUTURE, 2008, 33 (01) : 75 - 83
  • [39] The therapeutic landscape of hepatocellular carcinoma
    Gallage, Suchira
    Garcia-Beccaria, Maria
    Szydlowska, Marta
    Rahbari, Mohammad
    Mohr, Raphael
    Tacke, Frank
    Heikenwalder, Mathias
    [J]. MED, 2021, 2 (05): : 505 - 552
  • [40] GLUT-1 inhibition: A new therapeutic approach against hepatocellular carcinoma?
    Brito, A. F.
    Abrantes, A. M.
    Laranjo, M.
    Ribeiro, A. C.
    Goncalves, A. C.
    Sarmento-Ribeiro, A. B.
    Castro-Sousa, F.
    Tralhao, J. G.
    Botelho, M. F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S144 - S144